Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women

Obesity Clinical Trial

— LBC  

Official title:

Effects of Adding L-BAIBA to Exercising Adult Overweight and Obese Men and Women on Changes in Body Composition, Glucose Control, and Cardiometabolic Risk Factors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05775016
• Other study ID #: IRB-23-29
• Status: Recruiting
• Phase: N/A
• Start date: March 29, 2023
• Est. completion date: March 15, 2024

Study information

• Verified date: May 2023
• Source: Lindenwood University
• Contact: Anthony M Hagele, MS
• Phone: 636-949-4785
• Email: ahagele[@]lindenwood.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to examine changes in body composition, weight loss, glucose control, and cardiometabolic risk factors after adding supplementation of BAIBA to exercise in overweight and obese men and women.

Description:

This study will be conducted using a double-blind, placebo-controlled, parallel group design. Eligible study participants will be randomly assigned to one of three supplementation groups: placebo (resistant dextrin) supplementation + exercise group, 750 mg BAIBA supplementation + exercise group, and a 1500 mg BAIBA supplementation + exercise group. After signing an IRB-approved consent form, prospective participants will be scheduled for a screening visit where they will have their eligibility finalized through completion of a peak VO2 assessment using a motorized treadmill and metabolic cart. Eligible participants will then be fully explained the study and scheduled for a baseline testing session (week 0). Prior to scheduling this visit, participants must complete a 4-day food record. Once a food record is completed, participants will observe an overnight fast and be scheduled to complete the testing session between the hours of 0600 - 1000 hours. Upon arrival, changes in medical status, medications, and dietary supplements will be confirmed before having their body mass and hemodynamics assessed. Next, participants will have their waist circumference, body water (BIS), and body composition (DEXA) assessed to evaluate changes in body composition and obesity status throughout the study protocol. Participants will then have a venous blood sample collected for evaluation of health markers (complete blood counts, comprehensive metabolic panels, and lipid panels) before completing a resting metabolic rate measurement. The resting metabolic rate measurement will be used to prescribe energy intake throughout the study protocol. Participants will then use an electronic tablet and complete the Profile of Mood States and visual analog scales to evaluate perceptions of hunger and appetite. Participants will then be given their first daily dose. All participants will be given instructions and meal plans as well as be offered weekly educational sessions on how to restrict calories and meet protein goals throughout the study protocol. Participants will complete five days per week of exercise consisting of a mixture of walking and resistance training. Daily compliance to the exercise and supplementation groups will be monitored weekly for a 12-week period. Participants who complete at least 80% of their assigned workouts will be considered compliant and will be scheduled for follow-up visits after 6 and 12 weeks of supplementation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: March 15, 2024
• Est. primary completion date: March 15, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Participants who are between 18 - 60 years of age

• Body mass index values will range from >25.0 to < 32.0 kg/m2, making them qualified as an overweight-to-obese population (https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm)

• Average body mass index for entire study cohort will be less than 30.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 30.0 kg/m2

• Free-living/uninhibited with use of ambulatory assistive devices (e.g. canes, crutches, walkers, etc.) and independent

• In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders

• Willingness to maintain consistent sleep duration the evening before study visits

• Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures

• Able to complete a peak oxygen consumption exercise test with no contraindications to perform exercise per standards put forth by the American College of Sports Medicine. In other words, they are able to safety complete maximal exercise.

Exclusion Criteria:

• Positive medical history and/or is currently being treated for some form of heart disease, cardiovascular disease

• Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals

• Has liver disease or some form of clinically diagnosed hepatic impairment

• Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose > 126 mg/dL)

• Diagnosed with or is being treated for some form of thyroid disease

• Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year

• Diagnosed with some form of immune disorder (i.e., HIV/AIDS)

• History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).

• Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)

• Positive medical history for any neurological condition or neurological disease

• Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.)

• Current smoker (average of > 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine

• Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc.

• Participants who are lactating, pregnant or planning to become pregnant

• Have a known sensitivity or allergy to any of the study products

• History of alcohol or substance abuse in the 12 months prior to screening

• Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol

• They plan major changes in lifestyle (i.e., diet, dieting, exercise level, travel, etc.) during the study

• Recent history (<3 months) of exercise training or weight loss (> 5%)

• Any orthopedic limitation that would prevent participation in a general fitness program

• Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data

Related Conditions & MeSH terms

• Body Weight
• Cardiometabolic Syndrome
• Metabolic Syndrome
• Obesity
• Overweight
• Weight Loss
• Weight, Body

Intervention

Behavioral:
• Exercise
12 week resistance and cardiovascular exercise program

Locations

Country	Name	City	State
United States	Exercise and Performance Nutrition Laboratory	Saint Charles	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Lindenwood University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fat Mass (4-compartment)	Changes in Fat Mass (4-compartment)	12 weeks
Secondary	4-Compartment Lean mass	Changes in Lean Mass (4-compartment)	12 weeks
Secondary	Waist circumference	Changes in Waist circumference	12 weeks
Secondary	Visceral Fat (DEXA)	Changes in Visceral Fat (DEXA)	12 weeks
Secondary	Lean:Fat Ratio (DEXA)	Changes in Lean:Fat Ratio (DEXA)	12 weeks
Secondary	Body Mass	Changes in Body Mass	12 weeks
Secondary	Hunger and appetite visual analog scale	Changes in Hunger and appetite visual analog scale	12 weeks
Secondary	Profile of mood states (POMS)	Changes in Profile of mood states (POMS)	12 weeks
Secondary	Inflammatory markers (e.g. CRP, IL-6, etc.)	Changes in Inflammatory markers (e.g. CRP, IL-6, etc.)	12 weeks
Secondary	Comprehensive Metabolic Panel	Changes in Comprehensive Metabolic Panel	12 weeks
Secondary	Lipid Panel	Changes in Lipid Panel	12 weeks
Secondary	Self-reported adverse events	Occurrences of Self-reported adverse events	12 weeks